ALTO NEUROSCIENCE INC (ANRO:NYSE)
$25.47 -0.35 (-1.3555%)
Analysed ALTO NEUROSCIENCE INC (ANRO:NYSE) News Sources
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss
02-04-2026
yahoo.com
Sector Update: Health Care Stocks Softer Late Afternoon
02-04-2026
yahoo.com
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data
02-04-2026
yahoo.com
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
02-04-2026
biopharmadive.com
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
01-04-2026
yahoo.com
Alto Neuroscience CFO Nick Smith on Firm’s $120 Million Private Placement
23-03-2026
yahoo.com
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207
23-03-2026
yahoo.com
Alto Neuroscience Announces $120 Million Private Placement Financing
16-03-2026
yahoo.com
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
16-03-2026
yahoo.com
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
13-03-2026
yahoo.com
What is the current price of ALTO NEUROSCIENCE INC (ANRO:NYSE)?
The current price of ALTO NEUROSCIENCE INC (ANRO:NYSE) is $25.47.
ALTO NEUROSCIENCE INC (ANRO:NYSE) absolute price change since previous trading day?
The absolute price change of ALTO NEUROSCIENCE INC (ANRO:NYSE) since the previous trading day is $-0.35.
ALTO NEUROSCIENCE INC (ANRO:NYSE) percentage price change since previous trading day?
The percentage price change of ALTO NEUROSCIENCE INC (ANRO:NYSE) since the previous trading day is -1.3555%.
What is the most recent average sentiment score for ALTO NEUROSCIENCE INC (ANRO:NYSE)?
The most recent average sentiment score for ALTO NEUROSCIENCE INC (ANRO:NYSE) is 73 out of 100.
What is the most recent average sentiment for ALTO NEUROSCIENCE INC (ANRO:NYSE)?
The most recent sentiment for ALTO NEUROSCIENCE INC (ANRO:NYSE) is .
SEC-8K** Filing Available For ALTO NEUROSCIENCE INC (ANRO:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.